Literature DB >> 19650783

The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score.

Ioulietta Erotokritou-Mulligan1, E Eryl Bassett, David A Cowan, Christiaan Bartlett, Polly Milward, Alessandro Sartorio, Peter H Sönksen, Richard I G Holt.   

Abstract

BACKGROUND: Growth Hormone is abused by athletes for its lipolytic and anabolic properties. Its use is prohibited by the World Anti-Doping Agency. The GH-2000 project developed a methodology to detect its abuse using the concentrations of two GH-dependent biomarkers, IGF-I and type 3 procollagen (P-III-P). The sensitivity of this method may be improved by considering intra-individual variability. AIM: The aim of this study was to examine the intra-individual variability of IGF-I, P-III-P and the GH-2000 score. SUBJECTS AND METHODS: IGF-I, P-III-P and GH-2000 score were evaluated in four longitudinal studies involving 303 elite and 78 amateur athletes. Samples were collected over a period of up to 12 months from a total of 238 men and 143 women aged between 17 and 53 years (mean 24.2).
RESULTS: The four studies showed good agreement with no apparent difference in within-individual variation between amateur and elite athletes. The intra-individual variability for IGF-I ranged between 14-16% while the variability for P-III-P was 7-18%. No athlete tested positive for growth hormone during any of the studies. The overall mean intra-individual variability of the GH-2000 score was less than 0.6 units in all studies.
CONCLUSIONS: The high stability of marker levels suggests that concentrations are largely genetically determined. Adopting a test based on the concept of an athlete's 'passport' or 'profiling' would take advantage of this and most likely increase the sensitivity of the test. These data also provide strong evidence that a positive test result for GH abuse would not occur as a result of chance variability.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19650783     DOI: 10.1111/j.1365-2265.2009.03668.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

1.  Effects of muscular strength training and growth hormone (GH) supplementation on femoral bone tissue: analysis by Raman spectroscopy, dual-energy X-ray absorptiometry, and mechanical resistance.

Authors:  Robson Chacon Castoldi; Guilherme Akio Tamura Ozaki; Thiago Alves Garcia; Ines Cristina Giometti; Tatiana Emy Koike; Regina Celi Trindade Camargo; João Domingos Augusto Dos Santos Pereira; Carlos José Leopoldo Constantino; Mário Jefferson Quirino Louzada; José Carlos Silva Camargo Filho; William Dias Belangero
Journal:  Lasers Med Sci       Date:  2019-06-15       Impact factor: 3.161

Review 2.  Hormones as doping in sports.

Authors:  Leonidas H Duntas; Vera Popovic
Journal:  Endocrine       Date:  2012-09-19       Impact factor: 3.633

3.  Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps.

Authors:  Adelheid Soubry; Dora Il'yasova; Rebecca Sedjo; Frances Wang; Tim Byers; Clifford Rosen; Anatoli Yashin; Svetlana Ukraintseva; Steven Haffner; Ralph D'Agostino
Journal:  Int J Cancer       Date:  2011-09-14       Impact factor: 7.396

Review 4.  Detecting growth hormone misuse in athletes.

Authors:  Richard I G Holt
Journal:  Indian J Endocrinol Metab       Date:  2013-10

5.  IGF-I and IGFBP-1 in Relation to Body Composition and Physical Performance in Female Olympic Athletes.

Authors:  Emma Eklund; Anton Hellberg; Bo Berglund; Kerstin Brismar; Angelica Lindén Hirschberg
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-16       Impact factor: 5.555

6.  Multiple protein biomarker assessment for recombinant bovine somatotropin (rbST) abuse in cattle.

Authors:  Susann K J Ludwig; Nathalie G E Smits; Grishja van der Veer; Maria G E G Bremer; Michel W F Nielen
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

Review 7.  Growth hormone doping: a review.

Authors:  Ioulietta Erotokritou-Mulligan; Richard Ig Holt; Peter H Sönksen
Journal:  Open Access J Sports Med       Date:  2011-07-27

8.  Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.

Authors:  Artak Labadzhyan; L B Nachtigall; M Fleseriu; M B Gordon; M Molitch; L Kennedy; S L Samson; Y Greenman; N Biermasz; M Bolanowski; A Haviv; W Ludlam; G Patou; C J Strasburger
Journal:  Pituitary       Date:  2021-06-25       Impact factor: 4.107

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.